Boston Scientific Co. (NYSE:BSX) Shares Bought by Lifeworks Advisors LLC

Lifeworks Advisors LLC boosted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 29.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 6,027 shares of the medical equipment provider’s stock after purchasing an additional 1,374 shares during the period. Lifeworks Advisors LLC’s holdings in Boston Scientific were worth $538,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Van ECK Associates Corp lifted its holdings in Boston Scientific by 18.1% in the third quarter. Van ECK Associates Corp now owns 57,894 shares of the medical equipment provider’s stock valued at $5,063,000 after acquiring an additional 8,882 shares during the period. Impax Asset Management Group plc increased its holdings in shares of Boston Scientific by 17.5% during the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider’s stock valued at $457,138,000 after purchasing an additional 815,403 shares in the last quarter. Concurrent Investment Advisors LLC lifted its stake in shares of Boston Scientific by 5.8% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 9,724 shares of the medical equipment provider’s stock valued at $815,000 after purchasing an additional 530 shares during the period. M&G PLC purchased a new stake in Boston Scientific during the third quarter worth $1,327,000. Finally, Capital Performance Advisors LLP acquired a new stake in Boston Scientific during the third quarter valued at $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $99.15 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock’s 50 day moving average is $100.45 and its two-hundred day moving average is $91.19. The company has a market capitalization of $146.33 billion, a PE ratio of 79.32, a P/E/G ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 52-week low of $65.52 and a 52-week high of $107.17.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. upped their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Canaccord Genuity Group increased their price objective on Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a research note on Monday, December 9th. TD Cowen boosted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research report on Monday, March 3rd. Finally, Raymond James raised their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $108.91.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now directly owns 5,502 shares of the company’s stock, valued at $560,103.60. This represents a 75.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Daniel J. Brennan sold 15,087 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the sale, the chief financial officer now directly owns 241,451 shares of the company’s stock, valued at $25,369,256.57. This represents a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 137,322 shares of company stock valued at $14,321,068 in the last quarter. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.